U.S. medical equipment supplier Becton Dickinson will acquire C R Bard, in a $24 billion cash-and-stock deal, adding Bard's devices to its portfolio in the high-growth sectors of oncology and surgery, both companies said on Sunday.
Continue Reading Below
The deal comes two years after Becton Dickinson acquired CareFusion for $12 billion. It is the latest in a string of deals in the medical technology sector, as manufacturers turn to acquisitions to boost profit margins.
"We are confident that this combination will deliver meaningful benefits for customers and patients, as we see opportunities to leverage Becton Dickinson's leadership, especially in medication management and infection prevention," Bard Chief Executive Officer Tim Ring said in a statement.
The deal values Bard at $317 per share, a 25 percent premium over Friday's close of trading. Bard shareholders stand to receive $222.93 in cash and 0.5077 shares of Becton Dickinson for each of their shares, the companies said. This would lead to Bard shareholders owning about 15 percent of the combined company.
Becton Dickinson said the deal with Bard will expand its focus on the treatment of disease states beyond diabetes, to include peripheral vascular disease, urology, hernia and cancer.
"We will be able to partner (with providers) on fundamental treatment processes in a way that no one else can," Becton Dickinson CEO Vincent Forlenza said in an interview.
Becton Dickinson, based in Franklin Lakes, New Jersey, said it expected the acquisition to boost non-U.S. growth options in markets such as China, and to raise per-share earnings in fiscal year 2019. Some $300 million in annual "pre-tax run-rate cost synergies" are expected by 2020, the company said.
The medical device sector has seen several major deals in recent years, in response to a widespread slowdown in revenue growth, consolidation among healthcare providers, and increased pressure from healthcare payers to hold down treatment costs. In January, Abbott Laboratories acquired rival St. Jude Medical for $25 billion, while in 2015 Medtronic bought Covidien for around $49.9 billion, and Zimmer Holdings merged with Biomet for $13.4 billion, creating Zimmer Biomet Holdings.
"We expect that this deal will cause others in the space to take a step back and ask themselves if there is an opportunity to do another large transaction and should we be acting upon it," Forlenza said.
Becton Dickinson and Bard said they expected their deal to close in the fall of 2017, subject to regulatory and shareholder approvals.
Perella Weinberg Partners and Citigroup acted as financial advisers, and Skadden, Arps, Slate, Meagher & Flom was legal adviser to Becton Dickinson. Goldman Sachs was financial adviser and Wachtell, Lipton, Rosen & Katz was legal adviser to Bard.
(Reporting by Carl O'Donnell and Jonathan Spicer in New York; Editing by David Gregorio and Mary Milliken)